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We present a case of a poorly diﬀerentiated pseudomesotheliomatous carcinoma originating in the lung, which was manifested
with the distinctly rare complication of massive true hemothorax and persistent blood loss that proved rapidly fatal in spite of
surgery. Pseudomesotheliomatous carcinoma of the lung and neoplasia-associated hemothorax are reviewed and discussed.
1. Introduction
Massive, spontaneous hemothorax, is an unusual and rare
presenting sign of lung cancer [1]. This complication has, to
the best of our knowledge, not previously been reported con-
comitant with pseudomesotheliomatous carcinoma of the
lung. The term pseudomesothelioma refers to tumors that
simulate malignant mesothelioma clinically, radiologically,
or pathologically [2].
We hereby present a case of a poorly diﬀerentiated
lung carcinoma with extensive dissemination along the
pleural surfaces and interstitial growth pattern, including
angioinvasive growth, which manifested itself as massive
spontaneous true hemothorax. Immediate and repeated
thoracic surgery could not prevent death. The literature
on specific characteristics of lung cancer as a cause of
hemothorax is reviewed and discussed.
2. Clinical History
A 74-year-old Caucasian male was presented to the Emer-
gency Department with progressive dyspnea, existing for 5
days. There were no symptoms of cough, hemoptysis, or
fever and no preceding trauma. His medical history was
significant for a myocardial infarction and the placement
of a pacemaker because of bradycardia. In addition, he had
a ruptured aneurysm of the abdominal aorta 11 years ago,
for which he was treated with aortic bifurcation prosthesis.
He used acetylsalicylic acid but no other anticoagulant
medication. He was a smoker (50 pack years), and there
was no known exposure to asbestos. Clinical examination
revealed tachypnea with a respiratory rate of 26 breaths per
minute. Vital signs were all normal, and oxygen saturation
was 100% with 4 liters of oxygen per minute. Breath sounds
were absent on the right hemithorax. A chest radiograph
demonstrated a large amount of fluid in the right pleural
cavity. Laboratory analysis showed anemia (hemoglobin
[Hb] of 5.6mmol/L, normal range 8.5–11mmol/L). White
cell count, C-reactive protein, and coagulation time were
normal. A chest tube was placed, and 1200mL of blood
(Hb 3,6mmol/L) was drained immediately. In the first 24
hours, a total of 3 liters of blood was drained. A chest
computer tomography (CT) scan confirmed the hemothorax
(Figure 1), but no site of active bleeding or tumor could
be identified. There were no pathological mediastinal lymph
nodes.
2 Pathology Research International
1
1
2
3
Figure 1: Coronal CT scan image demonstrating the hemothorax
(1) with atelectasis of the right lung (2), mediastinal shift to the
left, and downward displacement of the liver (3), but no visible
intrapulmonary lesions or other signs of malignancy.
Blood loss persisted, demonstrated by a fall in Hb, despite
administration of 5 packed red blood cells. In addition, the
patient developed a fever (38.6◦C), and his C-reactive protein
and white cell count increased, suggesting an infected pleural
hematoma. Therefore, a right posterolateral thoracotomy
was performed and a large hematoma was removed. Bacterial
cultures remained negative. A bleeding ulcer was found in
the right upper lobe and was removed by wedge resection.
No other pleural lesions were observed at careful inspection.
Initially, the patient recovered uneventfully. On the
10th postoperative day, he acutely developed a hypovolemic
shock, again due to a hemothorax. A CT scan with
intravenous contrast showed a hemothorax but no focus
of active bleeding. The patient was stabilized with fluid
administration and packed red blood cells and underwent a
rethoracotomy. This time the pleura was thickened with an
irregular surface, macroscopically resembling carcinomato-
sis. The pleural surface showed diﬀuse bleeding, and 1.7 L
of blood was evacuated from the pleural cavity. To minimize
tumor-load and to obtain pleurodesis, a total pleurectomy
was performed, although there was no proof of malignancy
at that time. Intraoperative frozen section analysis was not
performed during this second operation since it was not
believed to change the course of treatment at that time.
On the third postoperative day, the patient developed
respiratory distress due to right lower lobe pneumonia.
The patient deteriorated despite antibiotics and supportive
treatment. Because of his locally advanced malignancy and
poor condition, both the patient and family requested
to discontinue treatment. The patient died 21 days after
initial presentation. A postmortem examination was not
performed.
3. Materials and Methods
The specimens were fixed in 4% buﬀered formalin, routinely
processed, and paraﬃn embedded. 4 μm-thick sections were
stained with hematoxylin-eosin (HE) and the following
standard stains: PAS, PAS-diastase, and elastica van Gieson.
Automated immunohistochemistry was performed on a
Ventana Nexus en Bond Max automated immunostainer
using antibodies for CAM5.2 (B&D), AE1/3 (Novocastra),
MOC31 (Novocastra), CK7 (Novocastra), CK20, 34βE12,
CK14 (Neomarkers), CK19, EMA, CEA (BioGenex), TTF-
1, SP-A, CD56 (Novocastra), chromogranin, synaptophysin,
calretinin, thrombomodulin, D2-40, CD31, CD34, Factor
VIII, E-cadherin, Mib-1, thyroglobulin, P53, S100, vimentin
(VUmc), and CDD99 (all from Dako if not otherwise
indicated) and was applied according to standard protocols.
Appropriate positive and negative tissue control samples
were used.
4. Results
4.1. Macroscopic Findings. The initial wedge resection
showed a slightly greyish thickening of the visceral and pari-
etal pleura at gross inspection. An ulceration of the visceral
pleura with adherent blood was recognized. Underneath
the visceral pleura an irregular and poorly defined greyish
consolidation of approximately 2 cmwas seen. There were no
other detectable masses present. There was no connection to
large airways.
4.2. Histological Findings. Microscopy revealed features of a
diﬀusely growing discohesive carcinoma, exclusively growing
in the alveolar interstitium, thus expanding it, while leaving
the original alveolar architecture intact (Figure 2). There
was local ulceration of the pleura, while, beyond this ulcer,
the tumor formed a thick cake of discohesive tumor cells
lining the pleural membrane (Figure 2(c)), with only focal,
microscopic invasion into the fatty tissue of the parietal
pleura.
The tumor consisted of atypical, moderately polymor-
phous, and irregularly shaped tumor cells with marked
discohesiveness. They featured scant eosinophilic cytoplasm
and irregularly contoured and hyperchromatic nuclei, often
containing one or more prominent nucleoli (Figure 2(b)).
There weremanymitoses and apoptoses present, but necrosis
was not observed. No squamous or glandular diﬀerentiation
was observed, andmucin stains (PAS-D and alcian blue) were
negative. Within the tumor, there were multiple small blood-
filled clefts and blood lakes. Angioinvasion in medium-sized
vessels, including an artery, was demonstrated (Figure 2(d)).
Of note, the broadened alveolar septa were lined by
markedly atypical epithelial cells, yet less atypical than the
interstitial carcinoma (Figures 2(a) and 2(b)). The atypia of
the lining cells extended beyond the tumor front, showing
a sharp demarcation with normal type I pneumocytes
(Figure 2(a)), a feature characteristic to nonmucinous ade-
nocarcinoma in situ with lepidic growth pattern (former
bronchioloalveolar carcinoma, BAC) [3].
4.3. Immunohistochemical Findings. There was partial weak
positivity for the keratin proteins CAM5.2 (Figure 2(e)),
CK14, and CK19, and strong positivity for vimentin, CD99,
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Figure 2: Histological and immunophenotypic features of the tumor: interstitial infiltrating growth pattern of a poorly diﬀerentiated
carcinoma ((a), detail in (b)) with atypical BAC-like pneumocytes lining the alveoli in (b) and around (a) the interstitial component of
the tumor (HE). The visceral pleura shows a cake of highly vascularized and poorly cohesive carcinoma ((c), HE), with cytonuclear features
similar to the interstitial infiltrating tumor in the lung. (d) The tumor invades into a medium-size vessel (elastica van Gieson stain). There
is strong immunoreactivity for CAM5.2 (e) and TTF-1 (f) in the atypical BAC-like component and variable immunoreactivity for CAM5.2
(e) and TTF-1 (f) in the infiltrating carcinoma.
and AE1/3. The tumor cells were nonreactive with EMA,
CEA,MOC31, CK7, CK20, 34BE12, SP-A, and S100 and only
mildly reactive with P53 and CD56. The neuroendocrine
markers chromogranin and synaptophysin were negative.
Calretinin, thrombomodulin, and D2-40, frequently posi-
tive in malignant epitheloid mesothelioma, were negative.
Because of its high vascularity, angiosarcoma was considered
in the diﬀerential diagnosis, but markers for vascular dif-
ferentiation (CD31, CD34, factor VIII) were negative in the
tumor cells. These markers did reveal the presence of a fine
network of thin-walled vessels within the tumor, including
many sinusoid-like vascular spaces. The tumor showed
near-diﬀuse staining for TTF-1, varying from negative to
strongly positive (Figure 2(f)). TTF-1 positive staining has
to our knowledge not been described in angiosarcomas or
mesotheliomas. On the basis of these findings, a histological
diagnosis of poorly diﬀerentiated adenocarcinoma of the
lung was made. Consistent with discohesive growth the
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tumor cells were negative for E-cadherin. Mib-1 was positive
in most tumor cells, confirming high proliferative activity.
Thyroglobulin was negative.
The atypical alveolar lining cells were uniformly and
strongly positive for TTF-1, CAM5.2, CK7, CEA, EMA, beta-
catenin, and surfactant A (Figures 2(e)–2(f)). There was a
diﬀuse weak positivity for p53.
4.4. Molecular Findings. No mutation in EGFR exons 19–
21 and KRAS exons 1-2 could be detected (PCR and
sequencing).
The second pleural resection showed an identical picture
of pleural cake with only focal microscopic invasion. As no
other lesions of the pleura were observed at surgery 10 days
before, this finding supports the suspected rapid progression
of the tumor.
5. Discussion
Many tumors feature metastases to the pleural membranes
in the late stage of the disease, but predominant serosal
involvement mimicking malignant mesothelioma is a rare
presenting sign [2]. Various malignant pseudomesothe-
liomatous tumors have been reported, including diﬀerent
types of primary lung carcinomas [2], a variety of sarcomas
[4], thymic epithelial tumors [4], melanoma [5], hematopoi-
etic neoplasms [4, 6], and many metastatic tumors [2, 4].
Pseudomesotheliomatous carcinomas originating in the lung
tend to be peripherally located and are characterized by
extensive pleurotropic growth and inconspicuous parenchy-
mal involvement [7]. Pseudomesotheliomatous lung carci-
nomas are a heterogenous group of tumors. Attanoos and
Gibbs reported 47 cases of primary pulmonary carcinoma
with extensive pleural spread of which 70% were adeno-
carcinomas [2]. Other reported types of lung carcinomas
mimicking malignant mesotheliomas include various high-
grade carcinomas such as pleomorphic carcinoma, small-
cell carcinoma, basaloid carcinoma, carcinosarcoma [2],
high-grade neuroendocrine carcinoma [8], and large-cell
carcinoma [9]. Also, squamous cell carcinoma, signet ring-
cell carcinoma [10], and atypical carcinoid [11] have been
reported. Pleural pseudomesotheliomatous tumors have
poor prognosis with a median survival of 8 months, similar
to stage IV non-small cell lung cancer [2, 12].
The presented case featured subpleural interstitial growth
and a pleural spread of discohesive tumor cells. In addition,
there were atypical BAC-like pneumocytes lining the alveoli
in and around the interstitial component of the infiltra-
tive tumor. These cells showed no nuclear stratification,
(micro)papillary or glandular diﬀerentiation present but
were strongly positive for TTF-1 and keratin markers,
suggestive of a BAC-component in a poorly diﬀerentiated
adenocarcinoma. Whether this represents a true in situ
component of the same adenocarcinoma, or reactive atypia,
cannot be distinguished with certainty. If considered to be in
situ carcinoma, then it can only be speculated as to whether
the interstitial component or the in situ component came
first, or even whether there could be an ongoing interchange
between the two. The constellation of an interstitial TTF-1
positive tumor together with atypia of the alveolar lining cells
is rarely observed in lung carcinomas. This combination,
however, is reminiscent of pneumocytoma [13]. Clearly, this
case diﬀers from pneumocytoma in that it represents a high-
grade and rapidly progressive tumor, a feature that has not
been described in pneumocytoma.
Our patient presented with a massive hemothorax which
required thoracotomy and wedge resection to control the
bleeding. After removal of the ulcerating lung lesion, the
hemorrhage recurred, resulting in severe anemia together
with circulatory failure and postoperative infection, causing
death 21 days after presentation. Bleeding from a lung cancer
usually presents as hemoptysis resulting from necrosis and
vascular rupture or tumor erosion of pulmonary vessels.
Approximately 7% of patients with lung cancermanifest with
hemoptysis, and centrally located bronchial tumors aremuch
more frequently associated with hemoptysis than peripheral
tumors [14, 15]. Patients with pseudomesotheliomatous car-
cinoma have not been reported to present with hemoptysis
[16].
Lung carcinoma is a distinctly uncommon cause of
hemothorax [17], and we found only one case reported
hitherto [1]. Spontaneous neoplasia-associated hemothorax
has most commonly been associated with neurofibromatosis
type 1, angiosarcoma, and hepatocellular carcinoma, the
latter known for its vascular stroma [17]. Mediastinal tumors
have also been reported to cause hemothorax [17]. Bleeding
caused by these tumors has been attributed to several
mechanisms. One is direct oozing or exsanguination of the
tumor into the pleural space, and another is acute bleeding
due to rupture of the primary tumor [18]. We believe that
both mechanisms could explain the intractable bleeding in
the present case, considering the serosal ulceration of the
primary lesion and multiple small blood-filled clefts and
vessels between the discohesive tumor cells. In addition,
tumor invasion into larger vessels including arteries, causing
vascular lesions, may have played a role [19].
Pleural eﬀusions are often seen together with pseu-
domesotheliomatous carcinomas of the lung [16, 20], and
these are frequently blood-stained (serosanguinous). True
hemothorax is defined as pleural fluid with a hematocrit
equal to or greater than 50% of the blood hematocrit [17].
Values of less than 50% have sometimes been called bloody
pleurisy [18]. Measuring the hematocrit (or hemoglobin
concentration) to distinguish between true hemothorax and
bloody pleurisy is important as these two conditions have
diﬀerent etiologies and therapeutic options [17].
Primary treatment of true hemothorax is by chest tube
drainage, which evacuates blood and prevents the formation
of a clotted hemothorax with restricted lung function. This
approach decreases the risk of empyema, and drainage
allows monitoring the amount of blood loss. However, in
case of persistent blood loss, as determined by chest drain
production or hemodynamic instability, surgical exploration
should be considered. Treatment of neoplasia-associated
hemothoraces depends on the tumor and frequently involves
resection of the lesion. The prognosis of malignancy-
associated hemothorax, as with pseudomesotheliomatous
carcinoma, is poor [17].
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We have presented a case of a rare type of poorly dif-
ferentiated pseudomesotheliomatous carcinoma originating
in the lung, complicated by massive true hemothorax and
persistent blood loss that proved rapidly fatal in spite of
surgery. Awareness of this rare complication is important
for an early diagnosis and intervention. Continued case
reporting is necessary to determine which protocols would
be optimal for treating this tumor.
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